AbbVie Inc. (ABBV) stock
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3086% above fair value
$286.01−6.81 (-2.33%)
Close on Nov 18, 2026Market cap $505.41BP/E 80.8Yield 2.33%
AbbVie free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
AbbVie's free cash flow for the twelve months ending Jun 30, 2026 was $18.21B, down 0.2% year over year. For fiscal 2025 it was $17.82B, down 0.1% from the year before. Over ten years it grew 9.8% a year on average. The highest annual figure on record is $24.25B in fiscal 2022.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.82B | -0.1% |
| FY2024 | Dec 31, 2024 | $17.83B | -19.2% |
| FY2023 | Dec 31, 2023 | $22.06B | -9.0% |
| FY2022 | Dec 31, 2022 | $24.25B | +10.3% |
| FY2021 | Dec 31, 2021 | $21.99B | +31.0% |
| FY2020 | Dec 31, 2020 | $16.79B | +31.5% |
| FY2019 | Dec 31, 2019 | $12.77B | -0.1% |
| FY2018 | Dec 31, 2018 | $12.79B | +35.6% |
| FY2017 | Dec 31, 2017 | $9.43B | +43.7% |
| FY2016 | Dec 31, 2016 | $6.56B | -6.3% |
| FY2015 | Dec 31, 2015 | $7.00B | +138.4% |
| FY2014 | Dec 31, 2014 | $2.94B | -49.2% |
| FY2013 | Dec 31, 2013 | $5.78B | -3.9% |
| FY2012 | Dec 31, 2012 | $6.01B | +2.1% |
| FY2011 | Dec 31, 2011 | $5.89B | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.11B | -36.2% |
| Q1 FY2026 | Mar 31, 2026 | $3.56B | +154.6% |
| Q4 FY2025 | Dec 31, 2025 | $4.89B | -27.6% |
| Q3 FY2025 | Sep 30, 2025 | $6.64B | +27.8% |
| Q2 FY2025 | Jun 30, 2025 | $4.88B | +140.6% |
| Q1 FY2025 | Mar 31, 2025 | $1.40B | -63.6% |
| Q4 FY2024 | Dec 31, 2024 | $6.76B | +48.6% |
| Q3 FY2024 | Sep 30, 2024 | $5.20B | -29.3% |
| Q2 FY2024 | Jun 30, 2024 | $2.03B | -66.9% |
| Q1 FY2024 | Mar 31, 2024 | $3.85B | -4.3% |
| Q4 FY2023 | Dec 31, 2023 | $4.55B | -37.0% |
| Q3 FY2023 | Sep 30, 2023 | $7.36B | -0.9% |
| Q2 FY2023 | Jun 30, 2023 | $6.14B | +26.3% |
| Q1 FY2023 | Mar 31, 2023 | $4.02B | -15.3% |
| Q4 FY2022 | Dec 31, 2022 | $7.22B | +47.6% |
| Q3 FY2022 | Sep 30, 2022 | $7.43B | -3.8% |
| Q2 FY2022 | Jun 30, 2022 | $4.86B | +3.6% |
| Q1 FY2022 | Mar 31, 2022 | $4.75B | +1.2% |
| Q4 FY2021 | Dec 31, 2021 | $4.89B | +6.8% |
| Q3 FY2021 | Sep 30, 2021 | $7.72B | +37.5% |
| Q2 FY2021 | Jun 30, 2021 | $4.70B | +61.2% |
| Q1 FY2021 | Mar 31, 2021 | $4.69B | +27.1% |
| Q4 FY2020 | Dec 31, 2020 | $4.58B | +47.0% |
| Q3 FY2020 | Sep 30, 2020 | $5.61B | +27.5% |
| Q2 FY2020 | Jun 30, 2020 | $2.91B | +24.0% |
| Q1 FY2020 | Mar 31, 2020 | $3.69B | +26.8% |
| Q4 FY2019 | Dec 31, 2019 | $3.11B | -4.8% |
| Q3 FY2019 | Sep 30, 2019 | $4.40B | +3.7% |
| Q2 FY2019 | Jun 30, 2019 | $2.35B | -14.6% |
| Q1 FY2019 | Mar 31, 2019 | $2.91B | +15.2% |
| Q4 FY2018 | Dec 31, 2018 | $3.27B | +36.1% |
| Q3 FY2018 | Sep 30, 2018 | $4.24B | +34.9% |
| Q2 FY2018 | Jun 30, 2018 | $2.75B | +46.6% |
| Q1 FY2018 | Mar 31, 2018 | $2.53B | +25.9% |
| Q4 FY2017 | Dec 31, 2017 | $2.40B | +68.3% |
| Q3 FY2017 | Sep 30, 2017 | $3.15B | +134.5% |
| Q2 FY2017 | Jun 30, 2017 | $1.88B | – |
| Q1 FY2017 | Mar 31, 2017 | $2.01B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.43B | – |
| Q3 FY2016 | Sep 30, 2016 | $1.34B | – |
See a number that looks wrong?